



Skolyn

Early. Accurate. Trusted.



Our Vision

A World Without Diagnostic Error

We are building a future where AI acts as a vigilant co-pilot for every clinician, ensuring no patient is left behind due to a missed diagnosis.

The Diagnostic Bottleneck is at a Breaking Point



49%

of radiologists report
severe burnout

(Source: Medscape Radiologist Lifestyle Report 2024)



~5%

clinically significant error rate in
radiological interpretations

(Source: Radiological Society of North America - RSNA)



\$75B

annual economic waste from
misdiagnosis & inefficiency (US + EU)

(Source: Healthcare Economics Research Consortium 2024)

Introducing Skolyn

The Clinical Co-Pilot

Augmented Accuracy

AI serves as a vigilant second reader, reducing diagnostic errors.

Accelerated Workflow

Reduce report turnaround time by up to 40%.

Unshakeable Trust

Explainable AI (XAI) eliminates the 'black box'—clinicians see what AI sees.



From Image to Insight in Seconds

1



Medical images are securely uploaded via HL7/FHIR integration with automatic quality validation.

2



Our deep learning model analyzes the image across 127 pathological indicators in <3 seconds.


3




Explainable AI shows exactly what the model detected, building clinician trust and enabling verification.

A Massive, Rapidly Growing Market

Medical Imaging AI Market Growth (2024-2030)



Source: Grand View Research Q2 2024



TAM
\$120B
Global Health IT

SAM
\$25B
(Medical Imaging AI by 2030)

SOM
\$250M
(Skolyn 5-Year Revenue Target)

A Proven B2B SaaS Model for Scalable, Recurring Revenue



Why We Win

A New Category of Transparent AI



Category Definition

The medical AI industry has faced a critical paradox: models achieved high accuracy but remained untrustworthy 'black boxes,' stalling clinical adoption. Our proprietary Explainable AI (XAI) architecture shatters this paradigm by making the AI's reasoning fully transparent and auditable. This creates the first and only category of AI that functions not as an opaque oracle, but as a trusted clinical co-pilot, finally uniting machine precision with the human confidence required for real-world care.

"Only Skolyn combines >95% accuracy with full explainability"

A Phased Strategy

Land, Prove, Expand, Scale



- 5+ paid pilot programs with Tier-1 hospitals
- 2+ peer-reviewed publications
- CE Mark certification secured
- 50,000+ scans processed

Achieve product-market fit and scale revenue

Phase 1: Clinical Validation

250K \$ ARR

5M \$ ARR

35M \$ ARR

Phase 2: Regional Expansion

Achieve product-market fit and scale revenue

- 25+ enterprise customers (Nordics + DACH)
- Strategic partnerships with 2-3 PACS vendors
 - ISO 13485 certification
- Expand to CT and MRI modalities

- FDA 510(k) clearance secured (US market entry)
- 100+ enterprise customers globally
- Platform expansion: prognostics + treatment planning
 - Series A fundraise (\$15M+)


Establish category leadership

Phase 3: Global Scale


A World-Class Team Bridging Medicine and AI



Aasa Feragen
Academic AI Advisor



Rolf Henrik Berg
MedTech Go-to-Market
& FDA Strategy Advisor



Tomas Landh
Clinical Bioethics Advisor



Murad Mammadov
Chief Executive Officer (CEO)
& Co-Founder



Olaf Yunus Laitinen Imanov
Chief Technology Officer (CTO)
& Co-Founder



Kayrahan Ozcan
Chief Product Officer (CPO)



Ahmet Yasir Duman
Chief AI Officer (CAIO)



Nurana Abdullayeva
Chief Regulatory Officer (CRO)



Hajiaga Sadikhov
Chief Information Officer (CIO)




Habib Mammadov
Backend Developer & Co-Founder



A High-Growth, Capital-Efficient Trajectory

Path to \$35M ARR with strong unit economics



Metric	Year 1	Year 2	Year 3	Year 4	Year 5
Customers	5	15	40	95	175
Avg ACV	\$50K	\$60K	\$65K	\$70K	\$75K
Gross Margin	75%	80%	83%	85%	85%
Annual Burn	\$1.2M	\$2M	\$2.5M	\$3M	Profitable
Headcount	12	20	35	60	85



- 1. Average 6-month sales cycle
- 2. 85% gross retention rate
- 3. 120% net retention (expansion)
- 4. Customer acquisition cost: \$45K
- 5. LTV:CAC ratio reaches 5:1 by Y3

The Ask

Fueling the Next Stage of Growth

Seeking a

\$2 Million

Seed Investment

This capital takes us to \$1.5M ARR and a break-even trajectory

Positions us for Series A (~18 months at a \$15M+ valuation)

De-risks regulatory pathway and validates clinical efficacy

\$2M Total Raise

Go-to-Market
25%

Product & Engineering
45%

Clinical & Regulatory
30%

Product & Eng.

45% (\$900K)

- Expand AI models to CT and MRI modalities
- Build enterprise-grade API and integration layer
- Hire 4 senior engineers + 1 ML researcher

Clinical & Reg.

30% (\$600K)

- Fund 5 paid pilot programs at Tier-1 hospitals
- Complete CE Mark certification process
- Publish 2+ peer-reviewed validation studies

Go-to-Market

25% (\$500K)

- Build initial sales team (2 AEs + 1 SE)
- Develop marketing collateral and clinical case studies
- Attend 4 major radiology conferences


Our 10-Year Vision

From Diagnosis to Prognosis

"The future of medicine is not about replacing clinicians - it's about empowering them with unprecedented intelligence."

- Murad Mammadov, CEO & Co-Founder

"Skolyn will evolve from a diagnostic tool into a comprehensive clinical intelligence platform. By integrating multi-modal data—genomics, lab results, EHRs, and imaging - we will not only detect disease but predict its course, guide personalized treatment decisions, and ultimately improve patient outcomes at population scale."



PREDICTIVE POPULATION HEALTH SYSTEM

Real-time health insights across entire populations

PROGNOSTIC CLINICAL INTELLIGENCE

Predicting disease progression, treatment response

MULTI-MODAL DIAGNOSTIC PLATFORM

Integrating labs, pathology, clinical notes

DIAGNOSTIC AI FOR MEDICAL IMAGING

X-ray, CT, MRI analysis with XAI



Thank You.

*Let's build the future of
diagnostics, together.*

Contact Name: Murad Mammadov

Title: CEO & Co-Founder

Email: murad.mammadov@skolyn.se

Website: www.skolyn.se

LinkedIn:

